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Exacerbations of obstructive airways diseases such as asthma and chronic obstructive pulmonary disease (COPD) may be associated with an increased number of neutrophilic granulocytes in the airways. This has been indicated by studies involving bronchoalveolar lavage (BAL) fluid and bronchial biopsy samples as well as induced sputum from patients [1±6] . Recent data suggest that this increased number of airway neutrophils is not associated with detectable airway infection [6] .
Neutrophils are capable of releasing mediators which cause effects that resemble exacerbations of obstructive airways disease. For example, neutrophils can release enzymes such as neutrophil elastase [7, 8] , a serine protease that degrades elastin and exerts a potent secretagogue effect on airway gland cells [8, 9] , and may thus contribute to lung tissue damage and to airway gland hypersecretion respectively [8, 10] . Neutrophils can also produce oxygen free radicals, which cause increased transcription of the messenger ribonucleic acid (mRNA) for the potent neutrophil chemoattractant interleukin (IL)-8 in bronchial epithelial cells [11±13] . Furthermore, neutrophils can release IL-8 in response to eosinophil granule major basic protein [14] , which is of interest because the number of eosinophils, just as the IL-8 level, is often increased in asthmatic airways [5, 15] . In addition to this, neutrophils can release the pro-inflammatory cytokine tumour necrosis factor-a (TNF-a) [16] , which is increased in obstructive airways disease [15] , and this cytokine can cause bronchial smooth muscle hyperresponsiveness [17] , possibly through the release of the CXC chemokine IL-8 from bronchial epithelial cells [17±19] . The recruitment and activation of neutrophils in the airways may therefore contribute to excacerbations of obstructive airways disease. This also means that factors controlling the mediators affecting neutrophil recruitment, such as CXC chemokines or tachykinins [12, 13, 20] , may play a role in triggering exacerbations of obstructive airways disease.
The role of T-lymphocytes
It is likely that T-lymphocytes of the CD4+ subset play a central role in the recruitment of granulocytes into the airway lumen in obstructive airways disease [2, 21±23] . For asthma, this is supported by the observation that specific antibodies directed against CD4+ cells inhibit allergen-induced influx of eosinophils and neutrophils into rodent airways in vivo and so do anti-IL-2 receptor antibodies [23, 24] , whereas it remains to be proven that this is the case in COPD. It is also noteworthy that neutrophils contain defensins that are capable of recruiting and modulating T-lymphocytes [8] , thereby providing a possible feedback mechanism between CD4+ cells and neutrophils. Whereas there is now massive evidence that IL-5 released from CD4+ cells plays a role in mediating allergen-induced eosinophil recruitment into asthmatic airways [25] , the mediator linking the activation of CD4+ cells to neutrophil recruitment has not yet been identified. IL-17 may be a candidate.
The interleukin-17 molecule IL-17 is a homodimeric protein comprising 23 amino acids and has a molecular weight ranging 15±22 kDa [24] . Rat (r), mouse (m) and human (h) IL-17 display a high degree of structural homology [24] . This homology includes the functionally important glycosylation site [24] .
Certain human and murine T-lymphocytes of the CD4+ subset can produce and release IL-17 when activated in vitro [26±28]. Thus, in patients with rheumatoid arthritis, IL-17 can be released from CD4+ cells isolated from synovial tissue and fluid in vitro and it appears that IL-17 is produced mainly by the T-helper (Th)0 and Th1 subsets of these cells [29] . In isolated human peripheral blood mononuclear cells in vitro, CD4+ as well as CD8+ memory T-cells (CD45RO) express IL-17 mRNA under certain conditions [30] , but the quantity of IL-17 released from CD4+ cells probably exceeds that from CD8+ cells [27] . IL-17 is probably not expressed constitutively under physiological conditions [26] .
Interleukin-17 receptors
Compared with other known receptor families, the receptor for IL-17 displays a unique structure [26, 28, 31] . The mRNA for the hIL-17 receptor is expressed in several human cell types, such as a lung epithelial cell line, foreskin fibroblasts, a B-cell line, a myelomonocytic cell line and a embryonal kidney cell line [31] . Several of these cell types express the hIL-17 receptor constitutively.
The mRNA for the mIL-17 receptor is distributed in several tissues including the lungs in mice [32] . When cultured in vitro, fibroblast, intestinal epithelial and Tlymphocyte cell lines from mice also express mRNA for the mIL-17 receptor [32] .
Interleukin-17 causes the release of neutrophilmodulating cytokines
Stimulation by hIL-17 causes human synovial fibroblasts to release IL-8 and granulocyte colony-stimulating factor in human synovial fibroblasts cultured in vitro [33] . Costimulation by hIL-17 together with hTNF-a results in release of granulocyte-macrophage colony-stimulating factor in these synovial fibroblasts. In response to IL-17, human foreskin fibroblasts cultured in vitro display increased expression of intercellular adhesion molecule-1 and produce IL-6 plus IL-8 [27] . As indicated in murine fibroblast cells in vitro, hIL-17 induces production of IL-6 through activation of the transcription protein nuclear factor-kB (NF-kB) [31] . Interestingly, hIL-17 also stimulates a human lung fibroblast lung cell line to produce IL-6 [33] and IL-6 release in human bronchial epithelial cells [33] . In addition, IL-17 also promotes granulopoiesis in mice [34] . For these reasons, IL-17 should have the capacity to mobilize airway neutrophils in vivo.
Interleukin-17 induces the release of a neutrophil chemoattractant
The neutrophil-recruiting capacity of IL-17 has recently been evaluated in vitro as well as in vivo [35] . It is now clear that hIL-17 increases the release of the neutrophil chemoattractant, IL-8 in a concentration-dependent fashion in a highly differentiated human airway epithelial cell line (16HBE) in vitro and that coincubation with a neutralizing anti-hIL-17 antibody blocks this IL-8 release [35] . IL-17 induces IL-8 release that is time-dependent in another human airway epithelial cell line (Calu-3) and in human umbilical vein endothelial cells (HUVEC's) [35] . This release of IL-8 is probably due to de novo synthesis because hIL-17 increases the hIL-8/b-actin mRNA ratios in 16HBE cells in vitro, as determined by reverse transcription polymerase chain reaction ( fig. 1) [35] . Interestingly, hydrocortisone reduces the hIL-17-induced increase in IL-8, in human airway epithelial (16HBE plus Calu-3) cells as well as in HUVEC's. Cotreatment with a submaximally effective concentration of hIL-17 and hTNF-a results in a substantial potentiating effect on IL-8 release from 16HBE cells [35] . The increase in IL-8 release caused by cotreatment with hIL-17 plus hTNF-a is even greater than that after treatment with a maximally effective concentration of hTNF-a alone, suggesting a synergistic stimulatory action of these two cytokines on the release of this potent neutrophil chemoattractant.
By taking conditioned medium from 16HBE cells cultured in vitro, and using this cell medium as a stimulus for isolated human neutrophils in a migration chamber in vitro, it has been shown that hIL-17 releases a chemotactic factor from these bronchial cells ( fig. 2) [35] . Also, a neutralizing anti-hIL-8 antibody blocks this indirect effect of hIL-17, showing that IL-8 is the chemotactic factor involved. In contrast to conditioned medium from 16HBE cells stimulated with hIL-17, hIL-17 per se has no direct chemotactic effect on the migration of human neutrophils in vitro [35] .
In a rat in vivo model, intratracheal instillation of hIL-17 significantly increases the absolute number of neutrophils in BAL fluid in a dose-dependent fashion ( fig. 3) [36] . This increase in BAL neutrophil number is detected 4, 6 and 8 h after instillation of hIL-17, indicating a sustained effect. When rats are pretreated with a neutralizing antibody directed against hIL-17, a significant reduction in the IL-17-induced increase in BAL neutrophils is observed, underlining the specificity of the effect of IL-17 [35] . When comparing the effect of hIL-17 to that of rIL-1b, a similar selectivity for neutrophil recruitment is observed [36] . In addition to this, it has now also been shown that selective neutrophil recruitment can be achieved by inducing overexpression of the IL-17 gene in mice airways [37] . Pretreatment with dexamethasone attenuates the hIL-17-induced increase in BAL neutrophils, thereby pointing out a steroid-sensitive mechanism of action in vivo as well as in vitro [35] . This provides additional evidence for the universal anti-inflammatory effect of glucocorticoids and supports the idea that glucocorticoids act, in part, via inhibition of cytokine production [38] .
The involvement of macrophage inflammatory protein-2 (MIP-2), the rat correlate to IL-8, has also been evaluated in rat airways in vivo, and the results confirm that hIL-17 instilled intratracheally increases the level of this CXC chemokine in BAL fluid [35] . The finding that pretreatment with a neutralizing antibody directed against mMIP-2 significantly reduces the increase in BAL neutrophil number caused by hIL-17 provides additional evidence for the involvement of MIP-2 [35] .
Interleukin-17 acts, in part, via endogenous tachykinins
The role of endogenous tachykinins in IL-17-induced airway neutrophilia has also been evaluated [36] . The results show that pretreatment with the peptidase inhibitors phosphoramidon plus captopril significantly enhances the number of neutrophils, but not that of other cell types, in BAL fluid from rats treated intratracheally with hIL-17 in vivo [36] . The relative magnitude of this effect is similar after corresponding treatment with rIL-1b [36] . In addition, pretreatment with phosphoramidon plus captopril does not significantly increase the neutrophil number in BAL fluid from rats treated with the vehicle of hIL-17 alone [36] , thereby suggesting that IL-17 acts, in part, via release of endogenous tachykinins. Also, in rats given hIL-17 intratracheally, pretreatment with phosphoramidon enhances the neutrophil number in BAL fluid, whereas captopril does not [36] . Furthermore, pretreatment with the selective neurokinin (NK)-1 receptor antagonist SR 140333 significantly reduces the neutrophil number in BAL fluid after treatment with hIL-17, but this is not the case after pretreatment with the selective NK-2 receptor antagonist SR 48968 [36] . Taken together, these observations point out the NK-1 receptor as an important target for IL-17-induced release of endogenous tachykinins.
Interleukin-17 activates neutrophils indirectly
The capacity of IL-17 to activate airway neutrophils has been evaluated by analysing the activity of two neutrophilrelated enzymes in the cell-free component of BAL fluid supernatant from rat airways in vivo [39] . A moderate increase in elastase activity is present after intratracheal treatment with hIL-17 [36] , and, in contrast, intratracheal instillation of rIL-1b alone does not cause a corresponding increase at an equally effective dose in terms of neutrophil recruitment. Rats pretreated with a threshold dose of rIL-1b display a significant enhancement of the elastase activity induced by hIL-17, whereas the BAL neutrophil count remains unaltered.
Quite similar to its effect on elastase activity, hIL-17 increases myeloperoxidase activity in cell-free BAL fluid supernatant, whereas IL-1b does not [39] . Pretreatment with a threshold dose of rIL-1b significantly enhances the myeloperoxidase activity induced by hIL-17, in analogy with its potentiating effect on hIL-17-induced elastase activity. Interestingly, in hIL-17-treated airways, the elastase activity correlates strongly with the myeloperoxidase activity, making a mechanistic association of elastase and myeloperoxidase release feasible.
By using a specific inhibitor of macrophage elastase (ethylene diamine tetra acetic acid) and neutrophil elastase 4-(z-Aminoethyl)-benzensulforylfluoride, respectively, a neutrophilic origin of the hIL-17-induced elastase activity has been ascertained [39] . In vehicle-treated rats, the inhibitor of macrophage elastase attenuates elastase activity in BAL fluid but this is not the case for the inhibitor of neutrophil elastase. In contrast, in hIL-17-treated rats, both the macrophage and the neutrophil elastase inhibitor attenuate elastase activity. Additional evidence in favour of hIL-17-induced neutrophil activation is provided by the strong correlation between the elastase activity sensitive to the neutrophil elastase inhibitor and myeloperoxidase activity [39] . There is no corresponding correlation between the elastase activity sensitive to the macrophage elastase inhibitor and myeloperoxidase activity.
In order to evaluate a hypothetical direct effect of IL-17, isolated rat neutrophils have been stimulated with hIL-17 in vitro [39] . However, the results show that hIL-17 causes no significant increase in myeloperoxidase activity in the conditioned cell medium of these neutrophils. The activation of airway neutrophils induced by hIL-17 is therefore likely to be an indirect effect.
Conclusions
Based upon the reviewed findings, it is concluded that IL-17, a cytokine released from certain activated T-lymphocytes, can play a pro-inflammatory role in the airways by recruiting and activating neutrophils (fig. 4) . The effect of IL-17 on neutrophil recruitment is, at least in part, mediated via induced CXC chemokine release, probably achieved through de novo synthesis. The induced release of CXC chemokine can be potentiated by TNF-a, a proinflammatory cytokine that is increased in obstructive airways disease [15] , and, interestingly, is released by macrophages stimulated with IL-17 [40] . IL-17 can also exert its action via induced release of endogenous tachykinins, which contribute to neutrophil recruitment by acting on NK-1 receptors. Just like the effect on neutrophil recruitment, IL-17 can exert an indirect stimulatory effect on neutrophil activity in the airways. It is likely that IL-17 activates airway neutrophils through the induced release of neutrophil-activating cytokines, such as IL-6 and IL-8, which are known to be released from the bronchial epithelium and fibroblasts by IL-17 [33] . Interestingly, IL-1b, another cytokine that is increased in obstructive airways disease [40] , does potentiate the stimulatory effect of IL-17 on neutrophil activation. It can be speculated that IL-17 stimulates the release of IL-1b from airway macrophages and that this IL-1b potentiates the IL-17-induced release of IL-6 and IL8 in bronchial epithelial cells [41, 42] .
Even though it has now been shown that there is increased immunoreactivity for IL-17 in asthmatic airways [43] , it is not known whether this increased immunoreactivity reflects the release of soluble biologically active IL-17 from CD4+ cells in the airway wall and/or lumen. Neither is it known whether the association of immunoreactivity for IL-17 and fibrotic areas in human bronchial tissue reflects a role of IL-17 in airway remodelling [43] . Yet another interesting issue is whether neutrophil activation and recruitment can account for the T-lymphocytedependent determination of airway responsiveness in vivo [44] , and whether IL-17 is involved in this context.
The hypothesis that interleukin-17 serves as a mediator linking the activation of certain CD4+ cells to the recruitment and activation of airway neutrophils clearly needs further evaluation. Hopefully, an increased understanding of these mechanisms will reveal novel targets for pharmacotherapeutical intervention against exaggerated recruitment and activation of neutrophils in obstructive airways disease. 
